Genomic data and prostate cancer risk classification: an update

Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer. … READ MORE …

Genomic testing for localized prostate cancer: an update

A relatively brief, current, full-text review article by Loeb and Ross is available on the Medscape web site and discusses the three currently available tests for assessment of genomic risk for men with localized forms of prostate cancer. … READ MORE …

Are genomic tests “up to snuff” for routine use in prognosis of prostate cancer risk?

The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …

Development of a standardized commercial test to “score” patients as eligible for active surveillance

A new paper to be presented at the Genitourinary Prostate Cancer Symposium has proposed development of a standardized method to “score” whether patients are suitable candidates for initial management on active surveillance. … READ MORE …

Prolaris test data change clinician, patient decisions about prostate cancer management

A new paper in the Journal of Urology provides us with some interesting if preliminary information on the ways that genetic/genomic tests of biopsy samples may be affecting first-line treatments for localized forms of prostate cancer. … READ MORE …

Medicare may soon cover Prolaris, Decipher tests for prostate cancer

Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of prostate cancer based on genetic/genomic analyses of tissue from biopsy and post-surgical samples. … READ MORE …

When test “validation” raises questions about levels of validity

There is something of a fuss emerging about data presented at the American Urological Association annual meeting and a claim that these data imply that Myriad Genetics’ genomic Prolaris test ‘has been “validated” in its ability to predict disease-specific death’. … READ MORE …